Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Immunotherapy with CD8+ T Cells for Metastatic Melanoma
NCT00553306Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2007
- Primary completion
- Aug 2010
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous CD8+ antigen-specific T cells in melanoma, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Safety and toxicity as assessed by NCI CTC version 3.0, Antitumor effects of CD4+ and CD8+ antigen-specific T-cells and 1 more. Started Sep 2007; status: completed.
02
Drugs
autologous CD8+ antigen-specific T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00553306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553306.